Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
11 pending office actions • 9 art units • 11 examiners • 0 of 11 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Aarhus Universitet manages 12 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 12 distinct examiners, resulting in a one-to-one ratio of actions to examiners. The workload is spread across 10 distinct art units, showing a high degree of technical diversity in the pending applications. This variety indicates that the university's research spans many different specialized fields within biotechnology and pharmaceuticals.
ALDARRAJI, ZAINAB MOHAMMED is the busiest examiner for the portfolio. This examiner is managing 1 busiest examiner pending office action. Because each of the 12 actions is assigned to a different examiner, the workload is distributed across the 12 distinct examiners. This decentralized prosecution environment requires managing 12 separate examiner relationships across 10 distinct art units. The high count of art units relative to the 12 actions suggests very little technical overlap between the pending cases, requiring a broad and adaptable prosecution strategy.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (27%) |
| §112 only | 1 (9%) |
| Double-patenting + other | 1 (9%) |
| Multi-statute (no §101) | 6 (55%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ALDARRAJI, ZAINAB MOHAMMED | 1 | 66.7% | +18.7% |
| LOPEZ, SEVERO ANTON P | 1 | 34.5% | +39.7% |
| BENZION, GARY | 1 | 21.1% | +13.7% |
| SHEN, YANXIN NMN | 1 | 90.0% | +22.5% |
| LOGSDON, CHARLES | 1 | 71.7% | +11.2% |
| PETKOVSEK, DANIEL | 1 | 83.5% | +9.4% |
| CHATTERJEE, JAYANTA | 1 | 45.5% | +80.0% |
| RIGA, MICHAEL ANGELO | 1 | 57.1% | +61.2% |
| GEBRESLASSIE, WINTA | 1 | 77.1% | +23.6% |
| WANG, CHANG YU | 1 | 33.5% | +53.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18681619 | AN OPTICAL SYSTEM FOR FREQUENCY CONVERSION OF A SINGLE PHOTON | PETKOVSEK, DANIEL | 30d overdue |
| 18541719 | SYNTHETIC ACTIVATION OF MULTIMERIC TRANSMEMBRANE RECEPTORS | CHATTERJEE, JAYANTA | 26d overdue |
| 19215441 | Means for Removing Saliva for Magnetic Resonance Imaging | ALDARRAJI, ZAINAB MOHAMMED | — |
| 18737606 | SYMRK PHOSPHORYLATION FOR ROOT NODULE ORGANOGENESIS | BENZION, GARY | — |
| 18605796 | GENETICALLY ALTERED NFR1 RECEPTOR KINASES | SHEN, YANXIN NMN | — |
| 18605686 | GENETICALLY ALTERED NFR5 RECEPTOR KINASES | LOGSDON, CHARLES | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18541719 | SYNTHETIC ACTIVATION OF MULTIMERIC TRANSMEMBRANE RECEPTORS | CHATTERJEE, JAYANTA | 26d overdue |
| 19215441 | Means for Removing Saliva for Magnetic Resonance Imaging | ALDARRAJI, ZAINAB MOHAMMED | — |
| 18866228 | HIGH-SPEED LASER SPECKLE CONTRAST IMAGING | LOPEZ, SEVERO ANTON P | — |
| 18737606 | SYMRK PHOSPHORYLATION FOR ROOT NODULE ORGANOGENESIS | BENZION, GARY | — |
| 18605796 | GENETICALLY ALTERED NFR1 RECEPTOR KINASES | SHEN, YANXIN NMN | — |
| 18605686 | GENETICALLY ALTERED NFR5 RECEPTOR KINASES | LOGSDON, CHARLES | — |
| 18570210 | SORLA MINI-RECEPTOR FOR TREATMENT OF ALZHEIMER'S DISEASE | RIGA, MICHAEL ANGELO | — |
| 18546953 | PET IMAGE ANALYSIS AND RECONSTRUCTION BY MACHINE LEARNING | GEBRESLASSIE, WINTA | — |
| Art Unit | Apps |
|---|---|
| 1662 | 2 |
| 3797 | 1 |
| 1681 | 1 |
| 1663 | 1 |
| 2874 | 1 |
| 1634 | 1 |
| 2677 | 1 |
| 1675 | 1 |
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19215441 | Means for Removing Saliva for Magnetic Resonance Imaging | ALDARRAJI, ZAINAB MOHAMMED | 3797 | §102§103 | Non-Final OA | — | Pending | May 22, 2025 |
| 18866228 | HIGH-SPEED LASER SPECKLE CONTRAST IMAGING | LOPEZ, SEVERO ANTON P | — | §103 | Non-Final OA | — | Pending | Nov 15, 2024 |
| 18737606 | SYMRK PHOSPHORYLATION FOR ROOT NODULE ORGANOGENESIS | BENZION, GARY | 1681 | §103§112 | Non-Final OA | — | Pending | Jun 07, 2024 |
| 18605796 | GENETICALLY ALTERED NFR1 RECEPTOR KINASES | SHEN, YANXIN NMN | 1663 | §102§103§112 | Final Rejection | — | Pending | Mar 14, 2024 |
| 18605686 | GENETICALLY ALTERED NFR5 RECEPTOR KINASES | LOGSDON, CHARLES | 1662 | §102§103§112 | Non-Final OA | — | Pending | Mar 14, 2024 |
| 18681619 | AN OPTICAL SYSTEM FOR FREQUENCY CONVERSION OF A SINGLE PHOTON | PETKOVSEK, DANIEL | 2874 | §103§112 | Non-Final OA | 30d overdue | Pending | Feb 06, 2024 |
| 18541719 | SYNTHETIC ACTIVATION OF MULTIMERIC TRANSMEMBRANE RECEPTORS | CHATTERJEE, JAYANTA | 1662 | §102§103§112 | Final Rejection | 26d overdue | Pending | Dec 15, 2023 |
| 18570210 | SORLA MINI-RECEPTOR FOR TREATMENT OF ALZHEIMER'S DISEASE | RIGA, MICHAEL ANGELO | 1634 | §112 | Non-Final OA | — | Pending | Dec 14, 2023 |
| 18546953 | PET IMAGE ANALYSIS AND RECONSTRUCTION BY MACHINE LEARNING | GEBRESLASSIE, WINTA | 2677 | §103 | Final Rejection | — | Pending | Aug 17, 2023 |
| 18040084 | NOVEL PEPTIDES AND USES THEREOF | WANG, CHANG YU | 1675 | §112DP | Non-Final OA | — | Pending | Jan 31, 2023 |
| 17276432 | METHODS AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCERS RESISTANT TO IMMUNE CHECKPOINT THERAPY | DENT, ALANA HARRIS | 1643 | §103 | Final Rejection | — | Pending | Mar 15, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial